The company adjusted its annual revenue forecast to a range of $91.6 million to $93.1 million, narrowing the upper bound from its previous $96 million estimate. This revision aligns closely with the $92.1 million consensus among analysts surveyed by FactSet. Alongside the revenue shift, Iradimed updated its earnings per share projections to $1.90–$1.94, while adjusted earnings are now anticipated to land between $2.07 and $2.11.

These adjustments follow a third-quarter performance that saw revenue climb to $24.2 million, bolstered by the market introduction of a new pump. Despite meeting analyst expectations for quarterly profit at 55 cents per share on an adjusted basis, the company’s outlook for the final quarter fell short of market projections. Iradimed expects fourth-quarter revenue between $25 million and $26.5 million, missing the $26.2 million target, while earnings estimates for the period also trailed consensus figures.